Background: As the main cellular ingredients of tumor microenvironment, tumor-associated macrophages (TAMs) play a vital role in tumor development and progression. Recent studies have suggested that TAMs are sensitive and specific prognostic factors in numerous cancers. The primary purpose of this study is to determine the prognostic significance of TAMs in intrahepatic cholangiocarcinoma (ICC). Methods: Immunohistochemical staining of CD68, CD86 and CD206 were performed in tissue microarrays containing 322 patients, who underwent surgical resection and were pathologically diagnosed with ICC. The prognostic value of CD68, CD86 and CD206 were evaluated by Kaplan-Meier analysis (log-rank test) and nomogram models. Results: We demonstrated that the CD86 + /CD206 + TAMs model was an independent prognostic index for ICC patients. Patients with low CD86 + TAMs and high CD206 + TAMs infiltration had a markedly worse prognosis and increased risk of post-operative recurrence when compared to high CD86 + TAMs and low CD206
INTRODUCTION
Intrahepatic cholangiocarcinoma (ICC), derived from the intrahepatic biliary tree, ranks second in the morbidity of liver malignancies (Blechacz & Gores, 2008) . Despite of the application of systemic therapy and novel targeted drugs, the prognosis of ICC patients remains poor, especially in advanced cases (Shaib et al., 2004) . Complete resection of the tumor lesion is the only potential curative option, but postoperative tumor recurrence or metastasis is inevitable, with a median overall survival of approximately 30 months (Farges et al., 2011; De Jong et al., 2011) . However, due to genetic complexity and tumor heterogeneity, the clinical outcomes of patients with parallel clinical and pathological characteristics may vary significantly. Current prognostic models based on integrated clinicopathologic features, such as carbohydrate antigen 199 , lymph node metastasis and tumor-node-metastasis (TNM) stage, may not be sufficient in predicting clinical outcomes of ICC patients. A more accurate prognostic model is warranted to be established to better predict clinical outcomes of ICC patients.
Accumulated studies have demonstrated that the tumor microenvironment is critical for tumor development and progression (Liotta & Kohn, 2001) . Macrophage is one of the various cellular ingredients involved in the formation of tumor microenvironment, in which they are commonly known as tumor-associated macrophages (TAMs). In response to different microenvironment signals, macrophages can alter their expression profile and transform into different phenotypes including M1 and M2 macrophages (Fridman et al., 2012; Murray & Wynn, 2011) . M1 macrophages ("killing" phenotype) are activated by toll-like receptor ligands and interferon-γ (IFN-γ), exhibiting anti-tumor properties. M1 macrophages also amplify Th1 responses, providing a positive feedback loop in anti-tumor response, while M2 macrophages ("healing" phenotype) are mainly stimulated by interleukin-4 (IL-4) or IL-13, inclined to facilitate tumor growth and progression (Murray & Wynn, 2011; Shi et al., 2015; Martinez & Gordon, 2014; Solinas et al., 2009; Mantovani et al., 2002) .
CD68 is the most commonly used marker for the study of TAMs, but it is not a specific marker of macrophages and cannot effectively distinguish M1 and M2 subtype macrophages (Falini et al., 1993) . In recent years, compelling evidence showed that M1 subtype macrophages expressed abundant CD86, CD38, Gpr18, Fpr2 and tumor necrosis factor a, whereas M2 subtype macrophages expressed high levels of CD206, CD163, Egr2 and c-Myc (Biswas & Mantovani, 2010; Olsson et al., 2015; Jablonski et al., 2015) . Recent studies found that M1 subtype macrophages possessed high levels of CD86, while M2 subtype macrophages expressed high levels of CD206 in human gastrointestinal tumors tissues (Hernandez et al., 2014; Zhu et al., 2015) .
Our previous study reported that low presence of CD86 + M1 TAMs and high presence of CD206 + M2 TAMs were significantly correlated with aggressive tumor phenotypes and worse prognosis in HCC patients . However, the profile of TAMs alteration and its correlation with ICC prognosis remain uncertain. In this study, we investigated the clinical relevance and prognostic significance of CD86 + /CD206 + TAMs in patients diagnosed with ICC.
MATERIALS AND METHODS

Clinical patients
A total of 322 ICC patients who underwent surgical resection and were pathologically diagnosed with ICC at Zhongshan Hospital, Fudan University (Shanghai, China) between May 2005 and April 2006 were enrolled in the study . Post-operative follow-up was consistent with harmonized standard. The clinicopathological and baseline demographic characteristics of the patients were retrospectively collected. OS was defined as the time frame from the date of operation to death, and recurrence-free survival time (RFS) was defined as the time interval from the date of surgery to recurrence . All patients were followed until recurrence of disease, death or lost to follow-up. This study was approved by the Clinical Research Ethics Committee of Zhongshan Hospital (No. y2017-179) and all patients provided written informed consent prior to the study. The consent inform is mainly concerned with informing patients of collecting their clinicopathological data without patient privacy exposure and obtaining biological samples for protein or genetic testing.
Immunohistochemistry
Protocols and details of tissue microarray (TMA) sections and immunohistochemistry (IHC) were performed as previously described . TMAs are produced using formalin-fixed paraffin-embedded (FFPE) ICC tissue samples. Representative regions were premarked in the paraffin-embedded tumor tissue. Sample cores were selected and taken from each representative ICC tissue. Serial sections (4 mm thick) were placed on slides coated with 3-aminopropyltriethoxysilane. IHC was performed using a two-step protocol. Paraffin sections were first deparaffinized and hydrated. After microwave antigen retrieval and neutralization of endogenous peroxidase, slides were preincubated with blocking serum and then incubated overnight with primary antibodies (anti-CD68 antibody, anti-CD86 antibody, Abcam; anti-CD206 antibody, Abcam; anti-CD31 antibody, Abcam; anti-LYVE1 antibody, diluted at 1:100, Abcam). Subsequently, the sections were serially rinsed, incubated with second antibodies. Positive staining was visualized with DAB (3, 3-diaminobenzidine), then counterstained with hematoxylin. The IHC staining of the TMA sections was evaluated manually under the microscope (DP73; Olympus, Tokyo, Japan). The positive staining cells were counted by Image Pro Plus 6.0 analysis software (Media Cybernetics, Bethesda, MD, USA) and the detailed procedure is described elsewhere (Brey et al., 2003) .The positive staining TAMs cells were identified as brown colored, irrespective of color depth, and were counted in five randomly selected visual fields under high magnification (×200). Representative low or high immunostaining density of CD68 + , CD86 + and CD206 + TAMs was recorded.
The immunohistochemical staining was evaluated independently by two experienced researchers blinded to the patients' clinical characteristics and outcomes.
The intra-observer reproducibility was tested by obtaining statistical κ-scores (Landis & Koch, 1977) . Based on the median values of CD68, CD86 and CD206 positive TAMs, the ICC patients were classified into high and low subgroups (Kuang et al., 2011) .
Multiple immunofluorescence labeling of formalin-fixed paraffin-embedded tissue
Multiple immunofluorescence labeling of FFPE tissue was performed as mentioned previously (Robertson & Isacke, 2011) . In brief, slides were dewaxed and rehydrated. Then transfer the slide rack into prewarmed target retrieval solution. After rinsed with PBS and immunofluorescence buffer, the samples were incubated with prediluted primary antibody, then washed with 1× PBS and incubated with corresponding secondary horseradish peroxidase-conjugated polymer for antibody conjugation. Fluorescein tyramide signal amplification plus (PerkinElmer, Waltham, MA, USA) was used for amplifying signals. After serials rinsing, slides were placed in specific retrieval buffer in microwave to remove redundant antibodies before the sequenced staining. Nuclei were counterstained with 4′-6-diamidino-2-phenylindole (DAPI) for 5 min. All slides were examined under a laser confocal microscope (Leica TCS SP5; Leica, Wetzler, Germany).
Statistical analysis
Statistical analyses were performed using SPSS software (20.0; SPSS, Inc., Chicago, IL, USA) and R software version 3.3.2. Univariate predictors of the status of immunohistochemical biomarkers (CD68, CD86 and CD206) were evaluated using the Pearson χ 2 test. OS and RFS curves were depicted using Kaplan-Meier method and compared with log-rank test. A Cox proportional hazards model was used to identify potential predictors and to assess the relationship between immunohistochemical biomarkers and survival. The statistically significant prognostic indicators for OS and RFS were selected to build nomogram models, using the "rms" package (R Foundation for Statistical Computing, Vienna, Austria). Furthermore, calibration plots and area under the receiver operating characteristic (ROC) curves (AUC) were used to evaluate the performance of the nomograms with "pROC" package (R Foundation for Statistical Computing, Vienna, Austria). A two-sided value of p < 0.05 was considered statistically significant.
RESULTS
Immunohistochemical and immunofluorescence characterizations of tumor-associated macrophages in ICC Patients
As shown in Fig. 1 , the positive staining of CD68, CD86 and CD206 were observed mostly in the cytoplasm of TAMs. Figure S1 showed the immunofluorescence staining and the colocalization of CD68 + , CD86 + and CD206 + macrophages in the same image.
The average levels of CD68 positive staining cells (median, 96 cells/field) was higher than that of CD86 positive staining cells (median, 57 cells/field) and CD206 positive staining cells (median, 61 cells/field, Fig. 2 ).
Correlations between intratumoral expression of TAMs and clinicopathologic characteristics in ICC patients
Based on the immunohistochemical findings of TAMs in 322 ICC patients, the potential correlation between TAMs and patients' clinical characteristics was evaluated. The associations were shown in Notably, several ICC prognostic studies indicated that preoperative serum CA-199 level was a significant prognostic indicator for ICC patients after hepatectomy (Bergquist et al., 2016; He et al., 2018; Juntermanns et al., 2010; Kondo et al., 2014; Zheng et al., 2017) . In general, high serum tumor marker CA-199 level was markedly associated with advanced tumor staging, increased risk for tumor recurrence, and poor OS (Bergquist et al., 2016; Juntermanns et al., 2010; Yoo et al., 2015) . Resected patients with CA19-9 elevation had similar peri-operative outcomes but decreased long-term survival (Bergquist et al., 2016) . However, some ICC patients with low preoperative serum level of CA-199 was associated with rapid disease progression (He et al., 2018) . Worse yet, a reliable tumor marker to distinguish the prognosis of CA-199 negative ICC patients remains limited.
To investigate the prognostic effect of CD86 + /CD206 + TAMs model in CA-199 negative patients (cut-off value 36 U/ml) (Chen et al., 2015) , 163 patients from the 322 ICC patient cohort were enrolled. In this CA-199 negative cohort, patients in CD86 high /CD206 low group had the best prognosis, while CD86 low /CD206 high group patients had the worst prognosis. The median OS of Group I, II, III and IV were 72.2, 57.4, 56.9 and 30.1 months (p = 0.002), respectively ( Fig. 5A ) and the median RFS of Group I, II, III and IV were 65.2, 46.0, 56.7 and 25.9 months (p = 0.005), respectively (Fig. 5B ).
Construction and validation of the nomogram
Independent prognostic indexes were identified through univariate analysis and forward stepwise (Bendel & Afifi, 1977 ) (Fig. 6A) . On the other hand, lymph node metastasis (p < 0.001), tumor multiplicity (p = 0.002) and CD86 + /CD206 + TAMs model (p = 0.005) were selected to build the RFS nomogram (Fig. 6B) . The summed-up points of each nomogram variable score indicated a Bold values indicate P < 0.05. a Patients were divided into four groups based on their staining densities of CD86 and CD206 positive TAMs: group I, high expression of CD86 but low expression of CD206; group II, both low expressions; group III, both high expressions; group IV, low expression of CD86 but high expression of CD206.
more accurate hierarchical prediction of patient outcomes. Higher total points are corresponding to worse OS and RFS probability. Internal validation of the nomograms was carried out by calibration plots with bootstrap sampling (m = 100, n = 1,000) (Harrell, Lee & Mark, 1996) . The C-indexes for the OS and RFS nomograms were 0.649 and 0.635, respectively. Both calibration plots were closely related to the 45-degree line (Figs. 6C-6F) . Additionally, the ROC was performed to further evaluate the nomograms (Linden, 2006; Robin et al., 2011) . The AUC was 0.6922 (95% CI [0.6312-0.7531]) for the OS nomogram (Fig. 6G ) and 0.6351 (95% CI [0.5736-0.6966]) for the RFS nomogram (Fig. 6H) . These results illustrated that the predicted and observed survival probabilities were in good concordance, and the goodness-of-fit was favorable.
DISCUSSION
In this study, the prognostic significance of CD86 + (Locatelli et al., 2016; Den Breems & Eftimie, 2016; Xu et al., 2014) . It was worth noting that M1 and M2 polarization phenotypes represent extremes of a spectrum. In some cases, a mixed M1/M2 phenotype would be produced in response to different external signals (Biswas & Mantovani, 2010; Lawrence & Natoli, 2011) . Moreover, there is always a dynamic switch between the different polarized statuses of TAMs in tumor microenvironment, which is depending on the local cytokine milieu. Under the circumstances of tumor progression, aberrant secretion of cytokines was often observed from tumor cells and their surrounding microenvironment, which educated macrophages to display trophic properties and switched to an immunosuppressive M2 polarization status (Senovilla et al., 2012) . CD68 + TAMs had no prognostic value in predicting the outcome of surgically treated ICC patients, which may be attributed to the inability of CD68 to distinguish between M1 and M2 subsets. This was consistent with previous studies in HCC, colon cancer and gastric cancer Hernandez et al., 2014; Zhang et al., 2015) . Therefore, CD86 and CD206 immunostaining were further examined to distinguish between M1 and M2 subtypes. could be utilized as powerful indicators for rational treatment decision, especially in CA-199 negative patients. Furthermore, we found that the blood microvessel count was significantly higher in the CD206 high tissues compared with the CD206 low tissues, which indicated that M2 macrophages may stimulate angiogenesis. This is consistent with other previous studies (Bronkhorst et al., 2011; Xue et al., 2019) . But there is no significant difference between the two groups in LMVD (p > 0.05) (Fig. S2C) . The result is consistent with a previous study (Zhang et al., 2011) which showed a positive correlation between M2-polarized TAM count and peri-tumoral LMVD, but not intra-tumoral LMVD in patients with lung adenocarcinoma. Since our study only included intra-tumoral samples, further study will test more samples and include peri-tumoral LMVD. In contrast to other prognostic markers, TAMs can also serve as therapeutic targets. Dong et al. (2017) identified that Fenretinide (4-HPR) could selectively inhibit M2 macrophage polarization through the inhibition of phosphorylation of STAT6, and in turn prevented the tumorigenesis of colorectal cancer. Recent studies have emphasized IFN-γ on its ability to switch immunosuppressive TAMs into immunostimulatory. Upon IFN-γ treatment, TAMs purified from ovarian cancer ascites recovered a M1 phenotype (IL-10 low , IL-12 high ), increased expression of CD86 and decreased level of ILT3, enhanced the proliferation of CD4 + T lymphocytes and improved the cytotoxic properties of CD8 + T cells clone (Duluc et al., 2009 ). Depletion of TAMs using clodronate-loaded liposomes (clodrolip) enhanced the effect of sorafenib in metastatic liver cancer models by anti-metastatic and anti-angiogenic effects (Zhang et al., 2010) . Moreover, TAMs depletion by GW2580, a selective pharmacologic inhibitor of CSF1R signaling, enhanced the anti-angiogenic and anti-tumor effects of VEGF/VEGFR2 antibodies in subcutaneous tumor models (Priceman et al., 2010) . All these data implied that TAMs could be a potential target for tumor treatment. In spite of its potential importance in the prognostic and therapeutic value of cancer, the mechanism macrophage recruitment into tumors is still not fully understood. Further studies are needed to shed light on the exact mechanism.
CONCLUSIONS
In conclusion, the present study demonstrated that the CD86 
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